Project Grant HT94252310983
Award Date 9/15/23
Completion Date 9/14/27
Dollars Obligated $920K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- This $2,131,064 federal Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to the University of Colorado-Denver supports research on the effects of androgen receptors in luminal breast cancer. The four-year project, titled "ANDROGEN RECEPTORS IN LUMINAL BREAST CANCER: EFFECTS ON RESPONSE TO ENDOCRINE THERAPY AND AN IMMUNE-SUPPRESSIVE TUMOR IMMUNE MICROENVIRONMENT (TIME)", aims to investigate how androgen receptor...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, a $624,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2027. The award supports research investigating androgen receptors as a novel therapeutic strategy for advanced thyroid cancer. This research initiative aligns with the Military Medical Research and...
- The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,260,839 Project Grant to the University of Colorado-Denver. The grant, titled "Targeting EHMT1/2 to Overcome Therapy-Resistant Ovarian Cancer," will fund advanced biomedical research aimed at developing novel diagnostic tools and therapeutic interventions for ovarian cancer. The research project, spanning from May 2025 to April 2029, will investigate the role of the...
- The University of Colorado was awarded a $577,680.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research to target EHMT1/2 to overcome therapy-resistant ovarian cancer. The project aims to transform healthcare for military service members, veterans, and the broader public by developing novel diagnostic tools, therapeutic interventions, and clinical practice guidelines to address critical health...
- This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
- The University of Colorado-Denver has been awarded a $1,130,984 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "DEFINING AND TARGETING CHROMOBOX2 (CBX2)-MEDIATED CHEMORESISTANCE IN HIGH GRADE SEROUS CARCINOMA". The grant will support the university's research efforts to investigate novel approaches for overcoming chemoresistance in high-grade serous carcinoma, a form of ovarian cancer, over a...
- This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
- The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
- The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
- The federal Project Grant award of $2,271,024.00 was provided by the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) federal grant program, to the University of Colorado-Denver. The award, effective November 1, 2024, supports a four-year research project to improve understanding of next-generation immunotherapy responses in metastatic uveal melanoma. The University of Colorado-Denver, a major public research university with a strong focus on medical...